Results 51 to 60 of about 2,835 (182)
Arthritis &Rheumatology, Volume 78, Issue 10, Page 2036-2049, October 2026.Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi +30 more
wiley +1 more source
Filgotinib for treating moderate to severe rheumatoid arthritis [PDF]
Prescriber, 2021 Filgotinib (Jyseleca) is a new oral janus kinase (JAK) inhibitor that has recently been approved by NICE for moderate or severe rheumatoid arthritis after failure of other disease‐modifying antirheumatic drugs (DMARDs). This article discusses its efficacy, side‐effects and place in therapy.
openaire +1 more source
Immunity, Inflammation and Disease, Volume 14, Issue 10, October 2026.ABSTRACT Background Crohn's disease (CD) is a multifactorial inflammatory bowel disease (IBD) characterized by impaired epithelial barrier integrity, excessive immune hyperactivation, and gut microbiota perturbations. Cumulative evidence supports the role of the intestinal epithelial barrier, immune system and gut microbiota in the progression of CD ...
Qing Lai +3 more
wiley +1 more source
Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1662-1674, October 2026.In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs +10 more
wiley +1 more source
ACR Open Rheumatology, Volume 8, Issue 9, September 2026.Objective This post hoc analysis evaluated the effect of zasocitinib, an investigational, oral, allosteric, highly selective, and potent tyrosine kinase 2 (TYK2) inhibitor in late‐stage clinical development, on TYK2 signaling response and disease‐related biomarkers and the association of these changes with clinical response in patients with active ...
Amit Choudhury +9 more
wiley +1 more source
Protective effect of filgotinib in rat endotoxin-induced uveitis model
International Ophthalmology, 2021 To investigate the protective effect of filgotinib in endotoxin-induced uveitis model in rats.This study used 24 Wistar Albino rats. Group I (control group) included the healthy controls; in Group II (sham group), only 300 µg/kg intraperitoneal (ip) lipopolysaccharide (LPS) was administered; and in Group III (treatment group), 3 mg/kg/day filgotinib ...
Murat Erdağ +6 more
openaire +3 more sources
JCC Plus, Volume 1, Issue 5, September 2026.Across 47 Phase 3 trials in Crohn's disease and ulcerative colitis, placebo exposure was associated with measurable harm. Disease exacerbation events showed the greatest excess risk, with one additional exacerbation occurring for every 8–13 patients assigned to placebo rather than active therapy.
Joëlle St‐Pierre +5 more
wiley +1 more source
Hepatitis E Infection in Patients With IBD Treated With Advanced Therapy: A Case Series
JCC Plus, Volume 1, Issue 5, September 2026.ABSTRACT Background and Aims Hepatitis E virus is an RNA virus with 8 genotypes. Infection is usually acute and asymptomatic, but chronic infection may develop in immunocompromised individuals. Data on the course of hepatitis E virus infection in patients with inflammatory bowel disease receiving advanced therapy are limited.
Jakub Jirsa +2 more
wiley +1 more source
JCC Plus, Volume 1, Issue 5, September 2026.This systematic review and meta‐analysis quantify absolute outcome differences of advanced therapies in moderate‐to‐severe ulcerative colitis, demonstrating significant benefits in clinical, endoscopic, and histological remission, and establishing a benchmark for evaluating novel or non‐pharmacological treatment strategies.
E. Visser +5 more
wiley +1 more source
Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial [PDF]
IMPORTANCE: Noninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options. OBJECTIVE: To assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment ...
Dick, Andrew D +16 more
core +1 more source